CCA
HBIO icon

Catalyst Capital Advisors’s Harvard Bioscience HBIO Stock Holding History

Catalyst Capital Advisors’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-26
Closed -$11K – 276
2013
Q3 		$11K Buy
+26
New +$1.02K 0.01% 275

Other funds holding HBIO

GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HSA
Hussman Strategic Advisors Ellicott City, Maryland $463M AUM 16% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Catalyst Capital Advisors's HBIO Position: Q3 2014 in Review

Catalyst Capital Advisors sold out of Harvard Bioscience (HBIO) in Q3 2014, closing a stake of 2,298 shares — an estimated $105K sold.

Catalyst Capital Advisors first reported a position in HBIO in Q3 2013 and held it in 4 quarters. The position peaked at $116K in Q1 2014. 72 funds tracked by Wall St. Rank hold HBIO as of Q3 2014.

  • Catalyst Capital Advisors reported no remaining Harvard Bioscience position as of Q3 2014 after selling out during the quarter.
  • Catalyst Capital Advisors sold 2,298 Harvard Bioscience shares in Q3 2014, an estimated $105K.
  • Catalyst Capital Advisors first reported a position in Harvard Bioscience in Q3 2013 and held it in 4 quarters.
  • Catalyst Capital Advisors's Harvard Bioscience position peaked at $116K in Q1 2014.
  • 72 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2014.

Based on Catalyst Capital Advisors's 13F filing for Q3 2014, filed 13 Nov 2014.